Tricuspid atresia medical therapy

Revision as of 21:10, 1 November 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-mgibson@perfuse.org +charlesmichaelgibson@gmail.com, -kfeeney@perfuse.org +kfeeney@elon.edu))
Jump to navigation Jump to search

Tricuspid atresia Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Tricuspid Atresia from other Disorders

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenarios

Pregnancy

Case Studies

Case #1

Tricuspid atresia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tricuspid atresia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tricuspid atresia medical therapy

CDC on Tricuspid atresia medical therapy

Tricuspid atresia medical therapy in the news

Blogs on Tricuspid atresia medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Tricuspid atresia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Keri Shafer, M.D. [2] Priyamvada Singh, MBBS [[3]]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [[4]]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Medical Therapy

ACC/AHA 2008 Guidelines - Recommendations for Medical Therapy - Tricuspid atresia (DO NOT EDIT)[1]

Class I
"1.Warfarin should be given for patients who have a documented atrial shunt, atrial thrombus, atrial arrhythmias, or a thromboembolic event.(Level of Evidence: C) "
Class IIa
"1.It is reasonable to treat systemic ventricle (SV) dysfunction with angiotensin-converting enzyme (ACE) inhibitors and diuretics.(Level of Evidence: C) "

ACC/AHA 2008 Guidelines - Recommendations for Management Strategies for the Patient with Prior Fontan Repair - Tricuspid atresia (DO NOT EDIT)[1]

Class I
"1.Management of patients with prior Fontan repair should be coordinated with a regional ACHD center. Local cardiologists, internists, and family care physicians should develop ongoing relationships with such a center with continuous availability of specialists.(Level of Evidence: C) "
"a.At least yearly follow-up is recommended for patients after Fontan repair.(Level of Evidence: C) "
"b.Arrhythmia management is frequently an issue, and consultation with an electrophysiologist is recommended as a vital part of care.(Level of Evidence: C) "
"c.New-onset atrial tachyarrhythmia should prompt a comprehensive noninvasive imaging evaluation to identify associated atrial/baffle thrombus, anatomic abnormalities of the Fontan pathway, or ventricular dysfunction.(Level of Evidence: C) "

References

  1. 1.0 1.1 Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.

Template:WH Template:WS